Majed Kanaan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Majed Kanaan has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Roman Gebauer
Department of Pediatric Cardiology Heart Center Leipzig, University of Leipzig Germany
3 shared publications - Anja Hanser
Department of Pediatric Cardiology and Intensive Care Medicine University Hospital Tübingen Tübingen Germany
2 shared publications Anna Kamphues
European Reference Network for Rare, Low Prevalence, or Complex Diseases of the Heart (ERN GUARD‐Heart) Germany
2 shared publications- Anselm Uebing
Department of Congenital Heart Disease and Pediatric Cardiology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany
2 shared publications Claudia Junge
Department of Pediatric Cardiology and Pediatric Intensive Care Medicine Hannover Medical School Hannover Germany
2 shared publications- Cordula Maria Wolf
Department of Congenital Heart Defects and Pediatric Cardiology German Heart Center Munich, TUM University Hospital, School of Medicine & Health, Technical University of Munich Munich Germany
2 shared publications
Latest Publications
- Open Access
- 30 August 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2638-2650
Brugada Syndrome in the Pediatric Population: Diagnostic Challenges and Clinical Outcome—Results of the German Multicenter Study COGIA
Introduction: Diagnosis and treatment of children and adolescents with suspected Brugada syndrome (BrS) is challenging. Aim of the study was to evaluate the applicability of current diagnostic criteria for pediatric patients with suspected BrS in the German multicenter study COGIA and to assess clinical outcome. Methods: Data analysis of 76 pediatric patients from 12 German tertiary care centers. Primary outcome was defined by the occurrence of a major arrhythmic event (MAE), secondary outcome by symptoms, pharmacotherapy and implantation of devices. MAE was defined as sudden cardiac death (SCD), aborted cardiac arrest (ACA) and appropriate implantable cardioverter‐defibrillator (ICD) therapy. Results: Criteria for BrS diagnosis were fulfilled in 39/76 pediatric patients (51.3%) according to ESC Guidelines, including 34 patients (44.7%) according to Shanghai Score. Genetic testing identified a (likely) pathogenic SCN5A variant in 31/66 tested children (47.0%) (14/30 with clinical diagnosis (46.7%) and 17/36 without clinical diagnosis (47.2%)). Twenty‐four patients (31.6%) showed a spontaneous type 1 ECG pattern, in 6 patients (7.9%) it was induced by fever. Ajmaline challenge was positive in 19/25 patients (76.0%). Syncope occurred in 15 patients (19.7%) and an ICD was implanted in 7 pediatric patients (9.2%). Four patients (5.3%) experienced a MAE (ACA), all of them fulfilling diagnostic criteria. “Symptoms at first consultation” was identified as an independent risk factor for MAE in the whole cohort (HR = 11.3, p = 0.04). Conclusion: Establishing the diagnosis of BrS remains challenging in the pediatric cohort. MAE occurred in 5.3% of patients with suspected BrS. Symptoms at first consultation increased risk for MAE. Clinical Trial Registration: The study is registered at the German Clinical Trial Register (DRKS) of the Federal Institute for Drugs and Medical Devices (BfArM), DRKS‐ID DRKS00028138.
- 30 August 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2638-2650
Open AccessBrugada Syndrome in the Pediatric Population: Diagnostic Challenges and Clinical Outcome—Results of the German Multicenter Study COGIA
Introduction: Diagnosis and treatment of children and adolescents with suspected Brugada syndrome (BrS) is challenging. Aim of the study was to evaluate the applicability of current diagnostic criteria for pediatric patients with suspected BrS in the German multicenter study COGIA and to assess clinical outcome. Methods: Data analysis of 76 pediatric patients from 12 German tertiary care centers. Primary outcome was defined by the occurrence of a major arrhythmic event (MAE), secondary outcome by symptoms, pharmacotherapy and implantation of devices. MAE was defined as sudden cardiac death (SCD), aborted cardiac arrest (ACA) and appropriate implantable cardioverter‐defibrillator (ICD) therapy. Results: Criteria for BrS diagnosis were fulfilled in 39/76 pediatric patients (51.3%) according to ESC Guidelines, including 34 patients (44.7%) according to Shanghai Score. Genetic testing identified a (likely) pathogenic SCN5A variant in 31/66 tested children (47.0%) (14/30 with clinical diagnosis (46.7%) and 17/36 without clinical diagnosis (47.2%)). Twenty‐four patients (31.6%) showed a spontaneous type 1 ECG pattern, in 6 patients (7.9%) it was induced by fever. Ajmaline challenge was positive in 19/25 patients (76.0%). Syncope occurred in 15 patients (19.7%) and an ICD was implanted in 7 pediatric patients (9.2%). Four patients (5.3%) experienced a MAE (ACA), all of them fulfilling diagnostic criteria. “Symptoms at first consultation” was identified as an independent risk factor for MAE in the whole cohort (HR = 11.3, p = 0.04). Conclusion: Establishing the diagnosis of BrS remains challenging in the pediatric cohort. MAE occurred in 5.3% of patients with suspected BrS. Symptoms at first consultation increased risk for MAE. Clinical Trial Registration: The study is registered at the German Clinical Trial Register (DRKS) of the Federal Institute for Drugs and Medical Devices (BfArM), DRKS‐ID DRKS00028138.
- 11 May 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (4) , 854-856
Transjugular closure of a large patent ductus arteriosus in a 1100-g infant
The patent ductus arteriosus is the most common cardiac anomaly in neonates. Haemodynamically significant patent ductus arteriosus is associated with increased morbidity and mortality in preterm babies. Transfemoral venous access is the standard route for patent ductus arteriosus device closure, even in very low birth weight infants. The transjugular approach is also an alternative, but it is more challenging, especially in preterm infants. We report a successful transjugular closure of a patent ductus arteriosus in a 1100‑g infant (the smallest worldwide), where transfemoral access was not possible due to bilateral iliofemoral venous thrombosis.
- 11 May 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (4) , 854-856
Transjugular closure of a large patent ductus arteriosus in a 1100-g infant
The patent ductus arteriosus is the most common cardiac anomaly in neonates. Haemodynamically significant patent ductus arteriosus is associated with increased morbidity and mortality in preterm babies. Transfemoral venous access is the standard route for patent ductus arteriosus device closure, even in very low birth weight infants. The transjugular approach is also an alternative, but it is more challenging, especially in preterm infants. We report a successful transjugular closure of a patent ductus arteriosus in a 1100‑g infant (the smallest worldwide), where transfemoral access was not possible due to bilateral iliofemoral venous thrombosis.
- 2 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (35) , 3453-3466
Long QT syndrome in children and adolescents: risk factors and outcomes in a large German cohort
Background and Aims: This study describes outcomes in a large contemporary national cohort of children and adolescents with long QT syndrome (LQTS). Methods: Data analysis of 548 paediatric LQTS patients at 12 German tertiary care centres. Primary outcome was the occurrence of a major arrhythmic event (MAE) defined as sudden cardiac death (SCD), aborted cardiac arrest (ACA) and appropriate implantable cardioverter-defibrillator (ICD) therapy before age 18 years. Results: Patients (48.9% male) presented at a median age of 6.3 (interquartile range 0.5–11.7) years with incidental findings (26.5%), symptoms (31.3%), and for cascade screening (42.2%). Primary outcome was reached in 58 patients (10.6%): SCD in 7 (1.3%), ACA in 40 (7.3%), and appropriate ICD therapy in 11 (2.0%), with an overall event rate of 1.0 per 100 patient-years at risk. During follow-up (before 18 years of age), 92.1% of patients received cardiac medication. An ICD was implanted in 73 patients (13.3%) of whom 25 (34.2%) received appropriate therapy. In multivariate analysis, the likelihood of experiencing a MAE was greater in patients with LQT3 [hazard ratio (HR) 2.5, 95% confidence interval (CI) 1.1–5.6, P = .03], syncope (HR 3.0, 95% CI 1.7–5.5, P < .01), absence of cardiac medication (HR 9.5, 95% CI 5.3–17.3, P < .01), and QTc ≥500 ms (HR 2.9, 95% CI 1.4–6.3, P < .01). In subanalyses, a pathogenic variant in the KCNH2 pore region of LQT2 patients and younger age at symptom presentation were identified as risk factors. Conclusions: Paediatric LQTS patients are at risk for life-threatening arrhythmias at <18 years of age and require a meticulous personalized clinical approach.
- 2 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (35) , 3453-3466
Long QT syndrome in children and adolescents: risk factors and outcomes in a large German cohort
Background and Aims: This study describes outcomes in a large contemporary national cohort of children and adolescents with long QT syndrome (LQTS). Methods: Data analysis of 548 paediatric LQTS patients at 12 German tertiary care centres. Primary outcome was the occurrence of a major arrhythmic event (MAE) defined as sudden cardiac death (SCD), aborted cardiac arrest (ACA) and appropriate implantable cardioverter-defibrillator (ICD) therapy before age 18 years. Results: Patients (48.9% male) presented at a median age of 6.3 (interquartile range 0.5–11.7) years with incidental findings (26.5%), symptoms (31.3%), and for cascade screening (42.2%). Primary outcome was reached in 58 patients (10.6%): SCD in 7 (1.3%), ACA in 40 (7.3%), and appropriate ICD therapy in 11 (2.0%), with an overall event rate of 1.0 per 100 patient-years at risk. During follow-up (before 18 years of age), 92.1% of patients received cardiac medication. An ICD was implanted in 73 patients (13.3%) of whom 25 (34.2%) received appropriate therapy. In multivariate analysis, the likelihood of experiencing a MAE was greater in patients with LQT3 [hazard ratio (HR) 2.5, 95% confidence interval (CI) 1.1–5.6, P = .03], syncope (HR 3.0, 95% CI 1.7–5.5, P < .01), absence of cardiac medication (HR 9.5, 95% CI 5.3–17.3, P < .01), and QTc ≥500 ms (HR 2.9, 95% CI 1.4–6.3, P < .01). In subanalyses, a pathogenic variant in the KCNH2 pore region of LQT2 patients and younger age at symptom presentation were identified as risk factors. Conclusions: Paediatric LQTS patients are at risk for life-threatening arrhythmias at <18 years of age and require a meticulous personalized clinical approach.
- Open Access
- 5 February 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (2)
Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED)
Aims: Landiolol, an ultra-fast acting super-selective beta-blocker, was investigated for the first time in Europe in a prospective clinical study for the management of supraventricular tachycardia (SVT) among paediatric patients. Methods and results: The LANDI-PED study was a prospective, multicentre, open-label, uncontrolled phase III study aiming to investigate the efficacy, safety, and pharmacokinetics (PK) of landiolol in paediatric patients. Sixty patients in surgical and non-surgical settings aged ≥1 day to <18 years with SVTs of various aetiologies received landiolol as a continuous intravenous infusion starting with 5 μg/kg/min titrated up to 40 μg/kg/min depending on heart rate (HR) reduction for up to a maximum of 24 h. The primary endpoint was restoration of normal sinus rhythm (NSR) within 210 min of infusion start. The primary endpoint was achieved in 15 (25.0%) patients. A total of 24 (40.0%) patients achieved a HR reduction of at least 20% within 210 min of landiolol infusion. A significant HR reduction was observed within minutes post-infusion, with a mean (±SD) reduction after 210 min of −13.2 (±11.5)% (P < 0.0001) in the overall population. By infusion end, 51.7% of patients achieved HR reduction of at least 20% from baseline and/or NSR conversion. The PK characteristics were consistent with the known profile of landiolol among adults. The most common adverse drug reaction was hypotension (10%). Conclusion: Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported. Clinical Trial Registration: EU Clinical Trial Register; EudraCT Number: 2015-001129-17.
- 5 February 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (2)
Open AccessLandiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED)
Aims: Landiolol, an ultra-fast acting super-selective beta-blocker, was investigated for the first time in Europe in a prospective clinical study for the management of supraventricular tachycardia (SVT) among paediatric patients. Methods and results: The LANDI-PED study was a prospective, multicentre, open-label, uncontrolled phase III study aiming to investigate the efficacy, safety, and pharmacokinetics (PK) of landiolol in paediatric patients. Sixty patients in surgical and non-surgical settings aged ≥1 day to <18 years with SVTs of various aetiologies received landiolol as a continuous intravenous infusion starting with 5 μg/kg/min titrated up to 40 μg/kg/min depending on heart rate (HR) reduction for up to a maximum of 24 h. The primary endpoint was restoration of normal sinus rhythm (NSR) within 210 min of infusion start. The primary endpoint was achieved in 15 (25.0%) patients. A total of 24 (40.0%) patients achieved a HR reduction of at least 20% within 210 min of landiolol infusion. A significant HR reduction was observed within minutes post-infusion, with a mean (±SD) reduction after 210 min of −13.2 (±11.5)% (P < 0.0001) in the overall population. By infusion end, 51.7% of patients achieved HR reduction of at least 20% from baseline and/or NSR conversion. The PK characteristics were consistent with the known profile of landiolol among adults. The most common adverse drug reaction was hypotension (10%). Conclusion: Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported. Clinical Trial Registration: EU Clinical Trial Register; EudraCT Number: 2015-001129-17.